JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Tel: +1-832-696-8203
Email: [email protected]
Worldwide Distributors
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
PAF (C16) is an endogenous platelet-activating factor (PAF) and ligand for PAF receptors. The platelet-activating factor receptor is a G-protein coupled receptor which binds platelet-activating factor.PAF is produced by inflammatory cells and polymorphonuclear neutrophils. It induces increased vascular permeability. To examine the loss of selective endothelial permeability, the extravasative effect of PAF was assessed by monitoring the plasma loss of 125I-albumin (6.7 nm), 125I-low density lipoproteins (22.0 nm) and 125I-very low density lipoproteins (62.1 nm). There was no selective plasma retention of the labeled plasma tracers, which suggest that PAF-induced extravasation is dose-dependent, with increases in vascular permeability [1].Given into the renal arterial circulation of male Wistar rats, PAF (C16) increased in renal blood flow (6-15%) in a dose-dependent way. The PAF-induced systemic hypotension and renal vasodilation are independent of renal innervation and are PAF-receptor mediated [2].References:[1]. Handley DA, Arbeeny CM, Lee ML, et al. Effect of platelet activating factor on endothelial permeability to plasma macromolecules. Immunopharmacology, 1984, 8(3-4): 137-142.[2]. Handa RK, Strandhoy JW, Buckalew VM Jr. Platelet-activating factor is a renal vasodilator in the anesthetized rat. Am J Physiol, 1990, 258(6 Pt 2): F1504-1509.